Market Overview

Morgan Stanley Sees Sapien Becoming Leading Product Line for Edwards Lifesciences

Related EW
Meet The 5 Companies Loving Obamacare
Edwards Lifesciences Shares Up Sharply Following Earnings Beat
Making Money With Charles Payne: 10/10/14 (Fox Business)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Edwards Lifesciences (NYSE: EW).

In the report, Morgan Stanley noted, “Sapien should prove to be the leading product line in transcatheter valves into '14 and beyond, supported by clinical data. The TAVR market is likely to continue its expansion, supported by better budgets in Europe, favorable clinical data in lower risk populations, and more deliverable products. A mitral replacement program could drive upside given the larger potential patient pool relative to the aortic space. Higher valve revenue mix supports higher GMs.”

Edwards Lifesciences closed on Thursday at $80.27.

Latest Ratings for EW

DateFirmActionFromTo
Nov 2014Sterne AgeeDowngradesBuyNeutral
Oct 2014Morgan StanleyMaintainsEqual-weight
Oct 2014CRT CapitalMaintainsBuy

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (EW)

Around the Web, We're Loving...

Get Benzinga's Newsletters